Table 4.
Post-sipuleucel-T ACI use in the subset of PSA-matched African American and Caucasian men with mCRPC treated with sipuleucel-T in PROCEED.
| Post-sipuleucel-T ACI use in sipuleucel-T-treated, PSA patients | ||
|---|---|---|
| African American patients (n = 219) |
Caucasian patients (n = 438) |
|
|
Number of post-treatment ACIs from five life-prolonging interventions in mCRPCa n (%) | ||
| 0 | 45 (21) | 113 (26) |
| 1 | 63 (29) | 99 (23) |
| 2 | 59 (27) | 100 (23) |
| 3 | 36 (16) | 80 (18) |
| 4 | 16 (7) | 41 (9) |
| 5 | 0 | 5 (1) |
| Mean number of ACIs (SD) | 1.6 (1.2) | 1.7 (1.3) |
| Median number of ACIs (range) | 2.0 (0–4) | 2.0 (0–5) |
| Specific post-treatment ACI, n (%) | ||
| Abiraterone | 123 (56) | 234 (53) |
| Enzalutamide | 110 (50) | 184 (42) |
| Docetaxel | 80 (37) | 194 (44) |
| Cabazitaxel | 36 (16) | 96 (22) |
| Radium-223 | 4 (2) | 20 (5) |
ACI anticancer intervention, mCRPC metastatic castration-resistant prostate cancer, PSA prostate-specific antigen, SD standard deviation.
aACIs were abiraterone, enzalutamide, docetaxel, cabazitaxel, or radium-223.